FDA approves gantry for IBA’s small-scale proton system

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

IBA announced this week that the FDA has provided marketing authorization for the gantry beam line designed for the company’s compact proton therapy system, which will be used much like its larger cousins for the treatment of a variety of cancers.

The new single-room system has a smaller footprint, but it also houses intensity modulated proton therapy (IMPT) capabilities. The pint-sized proton system has gone out to five locations, including China, Japan, France and Louisiana in the U.S.

"This is an exciting milestone for our customers in North America, where the cost of healthcare is a major focus,” said Olivier Legrain, IBA chief executive officer, in a press release. “The ProteusOne aligns with the U.S. healthcare trend of providing the highest quality of cancer treatment possible at the best possible price."

The first system is scheduled to be installed at the Willis-Knighton Cancer Centre in Shreveport, La, in late 2014.

"We are confident that ProteusOne will drive greater momentum in the adoption of this next generation targeted cancer treatment internationally,” added Legrain.
 

Kathy Mahdoubi

Related Content

Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes
Lizard saliva could be key to spotting elusive pancreatic tumors

Around the web

Cardiovascular Business
Positron partners with Upbeat Cardiology Solutions to improve cardiac PET/CT access

Positron, a New York-based nuclear imaging company, will now provide Upbeat Cardiology Solutions with advanced PET/CT systems and services. 

Cardiovascular Business
Global shortage of nuclear imaging isotopes may be over

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

Cardiovascular Business
‘A huge win’: CMS significantly increases Medicare payments for cardiac CT

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.